REFERENCES

• 1. Amanat N, McDonald M, Godfrey C, Bilston L, Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res, 2007;22:867-876.ArticlePDF
• 2. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res, 2009;41:721-729.Article
• 3. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with histrectomy: the women's health initiative randomized controlled trial. JAMA, 2004;291:1701-1712.Article
• 4. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab, 2007;92:911-918.Article
• 5. Bagger YZ, Tankó LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone, 2005;37:425-430.Article
• 6. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med, 2006;355:125-137.Article
• 7. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation : a meta-analysis of randomized controlled trials). JAMA, 2005;293:2257-2264.
• 8. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med, 2005;353:555-565.
• 9. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 2007;356:1809-1822.
• 10. Blake GM, Compston JE, Fogelman I. Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Miner Res, 2009;24:1354-1357.
• 11. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab, 2002;87:4528-4535.
• 12. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med, 2004;350:1189-1199.
• 13. Bonura F. Prevention, screening, and management of osteoporosis: an overview of the current strategies. Postgrad Med, 2009;121:5-17.
• 14. Bostrom MPG, Boskey A, Kaufman JK, Einhorn TA. Buckwalter JA, Einhorn TA, Simon SR. Form and Function of Bone. In: Orthopaedic basic science, 2000;2nd ed. Rosemont, IL, USA, AAOS. 319-369.
• 15. Briot K, Trémollières F, Thomas T, Roux C. Comité scientifique du GRIO. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine, 2007;74:24-31.
• 16. Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs, 2009;18:585-600.
• 17. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res, 2002;17:2237-2246.
• 18. Cesareo R, Napoletano C, Iozzino M, et al. Osteoporosis: recent physiopatologic acquisitions and new therapeutic perspectives. Minerva Endocrinol, 2009;34:255-262.
• 19. Chesnut CH 3rd, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res, 2005;20:1548-1561.
• 20. Chesnut CH 3rd, Silverman S, Andriano K, et al. PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med, 2000;109:267-276.
• 21. Civitelli R, Napoli N, Armamento-Villareal R. Use of intravenous bisphosphonates in osteoporosis. Curr Osteoporos Rep, 2007;5:8-13.
• 22. Committee for Physician's Guide of the Korean Society of Bone Metabolism. Physician's Guide for Diagnosis and Treatment of Osteoporosis, 2008;1st ed. Seoul, SeoHeung Co. 35-88.
• 23. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med, 2005;353:566-575.
• 24. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int, 2005;16:713-716.
• 25. Deal C. Future therapeutic targets in osteoporosis. Curr Opin Rheumatol, 2009;21:380-385.
• 26. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom, 2008;11:325-338.
• 27. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum, 2006;54:1838-1846.
• 28. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone, 2003;33:522-532.
• 29. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res, 2001;16:1846-1853.
• 30. DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ, 2010;340:b5463.
• 31. Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res, 2009;24:1662-1671.
• 32. Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA, 1999;282:637-645.
• 33. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res, 2004;19:745-751.
• 34. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med, 2003;349:1216-1226.
• 35. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab, 2001;86:4717-4726.
• 36. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett, 2008;18:923-928.
• 37. Geusens P. Emerging treatments for postmenopausal osteoporosis - focus on denosumab. Clin Interv Aging, 2009;4:241-250.
• 38. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone, 1998;22:455-461.
• 39. Gottschalck IB, Jeppesen PB, Holst JJ, Henriksen DB. Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scand J Gastroenterol, 2008;43:929-937.
• 40. Hamdy NA. Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc), 2008;44:7-21.
• 41. Heaney RP, Recker RR. Combination and sequential therapy for osteoporosis. N Engl J Med, 2005;353:624-625.
• 42. Henriksen DB, Alexandersen P, Hartmann B, et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone, 2007;40:723-729.
• 43. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone, 2009;45:833-842.
• 44. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev, 2005;26:688-703.
• 45. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med, 2006;354:669-683.
• 46. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract, 2009;2009:616054.
• 47. Kamiya N, Ye L, Kobayashi T, et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development, 2008;135:3801-3811.
• 48. Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone, 2003;33:293-300.
• 49. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone, 2005;37:148-158.
• 50. Khosla S, Melton LJ 3rd. Clinical practice. Osteopenia. N Engl J Med, 2007;356:2293-2300.
• 51. Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab, 2010;21:237-244.
• 52. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res, 2010;25:178-189.
• 53. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone( 1-34)]. Osteoporos Int, 2004;15:992-997.
• 54. Lane NE, Silverman SL. Anabolic therapies. Curr Osteoporos Rep, 2010;8:23-27.
• 55. Leupin O, Kramer I, Collette NM, et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res, 2007;22:1957-1967.
• 56. Lewiecki EM. Denosumab--an emerging treatment for postmenopausal osteoporosis. Expert Opin Biol Ther, 2010;10:467-476.
• 57. Lewiecki EM. Denosumab for the treatment of postmenopausal osteoporosis. Womens Health (Lond Engl), 2009;5:15-22.
• 58. Lewiecki EM. Denosumab update. Curr Opin Rheumatol, 2009;21:369-373.
• 59. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int, 2008;19:1363-1368.
• 60. Liberman UA, Weiss SR, Bröll J, et al. The Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med, 1995;333:1437-1443.
• 61. Liedert A, Kaspar D, Blakytny R, Claes L, Ignatius A. Signal transduction pathways involved in mechanotransduction in bone cells. Biochem Biophys Res Commun, 2006;349:1-5.
• 62. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/b-catenin signaling. J Bone Miner Res, 2009;24:1651-1661.
• 63. Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol, 2002;186:717-722.
• 64. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med, 2007;357:1799-1809.
• 65. MacLean C, Newberry S, Maglione M, et al. Systemic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med, 2008;148:197-213.
• 66. Management of osteoporosis in postmenoapausal women: 2010 position statement of the north American menopause society. Menopause, 2010;17:242-255.
• 67. Marie PJ. Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone, 2006;38:2 Suppl 1. S10-S14.
• 68. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am, 2003;32:253-271.
• 69. McClung MR. Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep, 2006;4:28-33.
• 70. Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int, 2009;20:1663-1673.
• 71. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med, 2004;350:459-468.
• 72. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep, 2009;7:18-22.
• 73. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res, 2005;20:1315-1322.
• 74. Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am, 2007;89:96-101.
• 75. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001;344:1434-1441.
• 76. Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int, 2009;84:453-461.
• 77. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int, 2009;20:315-322.
• 78. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem, 2005;280:7317-7325.
• 79. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J, 2005;19:1842-1844.
• 80. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ, 2005;330:1003.
• 81. Power J, Poole KE, van Bezooijen R, et al. Sclerostin and the regulation of bone formation: effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res, 2010.
• 82. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American college of physician. Ann Intern Med, 2008;149:404-415.
• 83. Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res, 2009;24:1358-1368.
• 84. Reginster J, Minne HW, Sorensen OH, et al. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int, 2000;11:83-91.
• 85. Reginster JY. Strontium ranelate in osteoporosis. Curr Pharm Des, 2002;8:1907-1916.
• 86. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum, 2008;58:1687-1695.
• 87. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab, 2005;90:2816-2822.
• 88. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med, 2002;346:653-661.
• 89. Romas E. Clinical applications of RANK-ligand inhibition. Intern Med J, 2009;39:110-116.
• 90. Ross FP. Rosen CJ. Osteoclast biology and bone resorption. In: Primer on the metabolic bone disease and disorders of mineral metabolism, 2008;7th ed. Washington, D.C., ASBMR. 16-22.
• 91. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 2007;297:1465-1477.
• 92. Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int, 2002;13:241-248.
• 93. Rowland KJ, Brubaker PL. Life in the crypt: a role for glucagon-like peptide-2? Mol Cell Endocrinol, 2008;288:63-70.
• 94. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int, 2008;19:733-759.
• 95. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric, 2002;5:390-398.
• 96. Schindeler A, Little DG. Bisphosphonate action: revelations and deceptions from in vitro studies. J Pharm Sci, 2007;96:1872-1878.
• 97. Seeman E, Boonen S, Borgström F, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone, 2010;46:1038-1042.
• 98. Shea B, Wells G, Cranney A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev, 2002;23:552-559.
• 99. Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum, 2007;37:1-12.
• 100. Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther, 2008;83:172-176.
• 101. Stoch SA, Zajic S, Stone J. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther, 2009;86:175-182.
• 102. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet, 2007;370:657-666.
• 103. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002;288:321-333.
• 104. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res, 2002;17:521-527.
• 105. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ, 2003;326:469.
• 106. Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem, 2009;284:10890-10900.
• 107. Vogel VG, Costantino JP, Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006;295:2727-2741.
• 108. Wermelin K, Suska F, Tengvall P, Thomsen P, Aspenberg P. Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone, 2008;42:365-371.

Table 1

Guideline for the medical treatment of the osteoporosis

Table 2

Recommendations for daily calcium intake

Table 3

Classification of the Bisphosphonates

Table 4

Methods of application of the bisphosphonates

Table 5

Effects of raloxifene

Table 6

Tibolone metabolites and hormonal receptors

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by  

• Effects of Extracts from Cnidium officinale and Angelica sinensis on Bone Fusion in Mice with Femoral Fracture
  Sang Woo Kim, Min-Seok Oh
  Journal of Korean Medicine Rehabilitation.2024; 34(2): 1.     CrossRef
• Treatment Options of Osteoporotic Vertebral Compression Fractures
  Yu Mi Kim, Tae Kyun Kim, Dae Moo Shim, Kyeong Hoon Lim
  Journal of the Korean Fracture Society.2018; 31(3): 114.     CrossRef
• Medical Treatment of Osteoporosis/Prevention of Falls
  Hyoung Keun Oh
  Journal of the Korean Fracture Society.2018; 31(4): 165.     CrossRef
• Cost-Effectiveness of Denosumab for Post-Menopausal Osteoporosis in South Korea
  Green Bae, Hye-Young Kwon
  Korean Journal of Clinical Pharmacy.2018; 28(2): 131.     CrossRef
• Survey on awareness and perceptions of bisphosphonate‐related osteonecrosis of the jaw in dental hygienists in Seoul
  Y‐J Mah, G‐Y Kang, S‐J Kim
  International Journal of Dental Hygiene.2015; 13(3): 222.     CrossRef